Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2851365 | 0.90 | TLR7 (0.74) | TLR7TLR8 | |
| SCHEMBL2850720 | 0.88 | TLR8 (0.72) | TLR7TLR8 | |
| SCHEMBL3706784 | 0.88 | TLR8 (0.72) | TLR7TLR8 | |
| SCHEMBL6419789 | 0.88 | TLR8 (0.93) | TLR7TLR8 | |
| SCHEMBL905197 | 0.87 | TLR7 (0.80) | TLR7TLR8 | |
| SCHEMBL21667553 | 0.86 | TLR8 (0.77) | TLR7TLR8 | |
| Hydrochloric Acid SCHEMBL2896839 | 0.86 | TLR7 (0.78) | TLR7TLR8 | |
| SCHEMBL853497 | 0.86 | TLR7 (0.73) | TLR7TLR8 | |
| SCHEMBL3699453 | 0.86 | TLR7 (0.74) | TLR7TLR8 | |
| SCHEMBL10310956 | 0.86 | TLR7 (0.71) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2432768-B1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-07-05 | — | — | EP | disclosed |
| US-9533978-B2 | Pyrimidine derivatives and their use in the treatment of cancer and further diseases | SUMITOMO DAINIPPON PHARMA CO., LTD (JP) | 2017-01-03 | — | — | US | disclosed |
| US-20150080396-A1 | Novel Pyrimidine Derivatives and Their Use in the Treatment of Cancer and Further Diseases | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2015-03-19 | — | — | US | disclosed |
| US-20120122867-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | ASTRAZENECA UK LIMITED (GB) | 2012-05-17 | — | — | US | disclosed |
| EP-2432768-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | AstraZeneca AB (SE) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010133885-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122867-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | TYMS, TYMP, DPYD | TLR7 2123/4885TLR8 4294/4885 |
| US-20150080396-A1 | Novel Pyrimidine Derivatives and Their Use in the Treatment of Cancer and Further Diseases | TYMS, TYMP, DPYD | TLR7 2123/4885TLR8 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.